<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="for many important viral pathogens, including HIV (11), RSV (12)," exact="influenza" post="(13), human DENV MBC derived antibodies were not fully"/>
 <result pre="develop severe dengue—referred to as dengue shock syndrome (DSS) or" exact="dengue hemorrhagic fever" post="(DHF)—which can further progress to organ failure and death."/>
 <result pre="which enabled them to isolate neutralizing mAbs against RSV and" exact="influenza" post="from human peripheral MBCs. Hybridoma technology is a well-established"/>
 <result pre="in humans that recognize RSV (52), Hepatitis C virus (54)," exact="influenza" post="(55), and DENV (56). Strengths and Limitations Immortalized B-cells"/>
 <result pre="13.WrammertJSmithKMillerJLangleyWAKokkoKLarsenCet al.. Rapid cloning of high-affinity human monoclonal antibodies against" exact="influenza" post="virus. Nature. (2008) 453:667–71. 10.1038/nature0689018449194 14.BeltramelloMWilliamsKLSimmonsCPMacagnoASimonelliLQuyenNTet al.. The human"/>
 <result pre="J Immunol Methods. (1983) 65:109–21. 10.1016/0022-1759(83)90308-36361139 37.SasakiSJaimesMCHolmesTHDekkerCLMahmoodKKembleGWet al.Comparison of the" exact="influenza" post="virus-specific effector and memory B-cell responses to immunization of"/>
 <result pre="immunization of children and adults with live attenuated or inactivated" exact="influenza" post="virus vaccines. J Virol. (2007) 81:215–28. 10.1128/JVI.01957-0617050593 38.AdamAWodaMKounlavouthSRothmanALJarmanRGCoxJHet al.."/>
 <result pre="55.EkiertDCFriesenRHBhabhaGKwaksTJongeneelenMYuWet al.. A highly conserved neutralizing epitope on group 2" exact="influenza" post="A viruses. Science. (2011) 333:843–50. 10.1126/science.120483921737702 56.NivarthiUKTuHADelacruzMJSwanstromJPatelBDurbinAPet al.. Longitudinal"/>
</results>
